Latest Conference Articles

May 2nd 2015, 5:11am

MDS Symposium

Amer Zeidan, MBBS, MHS, assistant professor of Medicine, Hematology, Yale Cancer Center, discusses a population-based study of subsequent myelodysplastic syndromes (MDS) in prostate cancer patients after radiotherapy.

May 1st 2015, 12:39pm

MDS Symposium

Treatment with T-cell depleted transplantation was associated with a lower incidence of acute graft versus host disease (GVHD) and a very low incidence of chronic GVHD compared with unmodified allografts in patients with advanced myelodysplastic syndrome.

May 1st 2015, 11:20am

MDS Symposium

Treatment with lenalidomide (Revlimid) versus placebo improved health-related quality of life (HRQoL) after 24 weeks for patients with myelodysplastic syndromes.

May 1st 2015, 7:23am

MDS Symposium

Treatment strategies for patients with myelodysplastic syndromes are built upon a foundation of supportive care, which consists of transfusions, iron chelation, and growth factor therapy.

May 1st 2015, 6:15am

MDS Symposium

Sara M. Tinsley, MS, PhD, ARNP, AOCN, nurse practitioner, malignant hematology, Moffitt Cancer Center, discusses a study that examined quality of life in patients with high-risk myelodysplastic syndromes (MDS).

May 1st 2015, 5:30am

MDS Symposium

Rami S. Komrokji, MD, clinical director, Department of Malignant Hematology, H. Lee Moffitt Cancer Center, discusses a study that examined risk stratification of therapy-related MDS.

April 30th 2015, 1:22pm

MDS Symposium

OncLive spoke with Guillermo Garcia-Manero, MD, regarding the significance of sotatercept and rigosertib and their potential as therapies in MDS.

April 30th 2015, 11:52am

MDS Symposium

HLA-matched allogeneic hematopoietic stem cell transplantation was associated with more than a doubling in 4-year overall survival rates for patients with intermediate-2 or high-risk myelodysplastic syndromes.

April 30th 2015, 10:29am

MDS Symposium

Bart L. Scott, assistant member, clinical research division, Fred Hutchinson Cancer Research Center, discusses a new registry that will collect data from patients with MDS.

April 30th 2015, 7:30am

MDS Symposium

Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the multikinase inhibitor rigosertib in patients with MDS who have failed hypomethylating agents.

April 30th 2015, 5:22am

MDS Symposium

The first-in-class activin receptor antagonist sotatercept stimulated erythropoiesis in nearly half of patients with MDS and non-proliferative CMML following failure on erythropoiesis-stimulating agents.

April 28th 2015, 1:54pm

MDS Symposium

Interview with Thomas Prebet MD, PhD, in advance of the 2015 International MDS Symposium, on topics related to supportive care in MDS and iron chelation therapy.

April 28th 2015, 8:02am

Oncology Nursing Society Congress

Portal vein thrombosis is a dangerous and often overlooked side effect of certain gastrointestinal malignancies such as liver and pancreatic cancer, that oncology nurses need to be more proactive in managing.

April 23rd 2015, 8:34am

AACR Annual Meeting

D. Ross Camidge, MD, director, Thoracic Oncology Clinical Program, program director, Thoracic Oncology Clinical and Translational Research Fellowship, University of Colorado Denver, discusses MET and if it is still a relevant target in lung cancer.

April 22nd 2015, 11:24am

AACR Annual Meeting

Robert C. Bast, Jr., MD, vice president, Translational Research, The University of Texas MD Anderson Cancer Center, discusses a study that could help in early detection of ovarian cancer before CA-125 rises in patients.

April 22nd 2015, 11:01am

AACR Annual Meeting

The combination of olaparib with the novel AKT-targeting agent AZD5363 generated responses in a variety of tumor types among patients with and without BRCA1/2 mutations, demonstrating that a simultaneous attack on the two pathways is a safe and potentially versatile strategy.

April 22nd 2015, 10:38am

AACR Annual Meeting

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discuses the impact of the FDA's approval of nivolumab's for the treatment of squamous non-small cell lung cancer.

April 21st 2015, 12:23pm

AACR Annual Meeting

A two-pronged strategy combining the PARP inhibitor olaparib and the PI3K inhibitor BKM120 proved to be a safe and clinically beneficial regimen for women with triple-negative breast cancer and for patients with high-grade serous ovarian cancer.

April 21st 2015, 11:29am

AACR Annual Meeting

Elizabeth A. Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses nelipepimut-S (NeuVax) and a proposed trial for patients with ductal carcinoma in situ (DCIS).

April 21st 2015, 8:44am

AACR Annual Meeting

Treatment with olaparib demonstrated a durable overall response rate of 87.5% in a biomarker-defined subgroup of men with pretreated sporadic metastatic castration-resistant prostate cancer in a phase II multi-step adaptive trial.